SCHEMBL4357487

SCHEMBL4357487

Cc1ccc(C=C2SC(N3CCN(c4ccccc4)CC3)=NC2=O)cc1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 1/20 0.78
MAPT P10636 8/20 0.75
RAB9A P51151 1/20 0.73
ALDH1A1 P00352 4/20 0.68
L3MBTL1 Q9Y468 3/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
HPGD P15428 2/20 0.65
SENP1 Q9P0U3 1/20 0.64
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
POLB P06746 2/20 0.63
GRIN1 Q05586 3/20 0.61
GRIN2B Q13224 3/20 0.61
ALOX5 P09917 1/20 0.57
MAPK1 P28482 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
HTT P42858 1/20 0.57
ENPP2 Q13822 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4357485 1.00 DCTPP1 (0.78) DCTPP1MAPTRAB9AALDH1A1L3MBTL1
SCHEMBL4348476 0.88 DCTPP1 (0.78) DCTPP1MAPTRAB9AALDH1A1L3MBTL1
SCHEMBL4348473 0.88 DCTPP1 (0.78) DCTPP1MAPTRAB9AALDH1A1L3MBTL1
SCHEMBL4358838 0.86 MAPT (1.00) MAPTRAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL4358837 0.86 MAPT (1.00) MAPTRAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL4364828 0.85 GRIN1 (0.80) DCTPP1MAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL4364826 0.85 GRIN1 (0.80) DCTPP1MAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL4347335 0.85 MAPT (0.79) MAPTRAB9AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL4347336 0.85 MAPT (0.79) MAPTRAB9AALDH1A1L3MBTL1SMN1; SMN2
Bromide SCHEMBL4357470 0.84 MAPT (0.77) MAPTRAB9AALDH1A1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 DCTPP1 167/4885MAPT 1470/4885RAB9A 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.